Skip to Content

EADV 2026: Advances in Targeted Treatment of Hidradenitis Suppurativa

New targeted therapies are expanding treatment options for patients with hidradenitis suppurativa (HS). In this MEDtalk from the EADV Congress 2026, Thrasyvoulos Tzellos, MD, PhD, Associate Professor, University of Tromsø, Norway, discusses the emerging role of JAK inhibitors alongside TNF and IL-17 inhibitors. Key topics include individualized treatment, achieving long-term remission, and the potential of combining targeted therapies with surgery.

Thrasyvoulos Tzellos

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top